Seres Aims To File C. Diff Microbiome Drug On Single Pivotal Trial
Competing with several other firms to bring the first microbiome-derived therapy to market, Seres says the magnitude of its Phase III efficacy compared to placebo may enough for registrational filing.
You may also be interested in...
Tomas de Wouters, one of In Vivo’s 2020 Rising Leaders, has taken on the complex challenge of the microbiome, aiming to design the next generation of microbiome therapeutic candidates targeted at host-microbial interactions.
"There's a lot of hope and hype still in the microbiome sphere," Ferring's president Per Falk tells Scrip, but the rewards could be considerable for companies that can deliver well-documented safety and efficacy data and do not take try to take shortcuts.
After a trial failure in 2016, four rival companies could produce pivotal data this year